Colorectal cancer (CRC) remains the third most commonly diagnosed cancer, ranking
second among the most common causes of cancer‐related mortality. Immune checkpoint …

Introduction. In recent years, immune checkpoint inhibitors (ICIs) have attracted widespread
attention and made breakthroughs in progress towards the treatment of various cancers …

Receptor-interacting protein kinase 3 (RIPK3) is essential for mucosal repair in inflammatory
bowel diseases (IBD) and colorectal cancer. However, its role in tumor immunity is unknown …

Background Colorectal cancer (CRC) is the second leading cancer killer in the US today
and patients with metastatic disease have only a 14% 5-year survival. One of the most …

Colorectal cancer (CRC), known for its high metastatic potential, remains a leading cause of
cancer-related death. This review emphasizes the critical role of immune responses in CRC …

The PI3K pathway is one of the most frequently altered signaling pathways in human cancer.
In addition to its function in cancer cells, PI3K plays a complex role in modulating anti-tumor …

Immune checkpoint blockade has revolutionized cancer treatment. Patients developing
immune mediated adverse events, such as colitis, appear to particularly benefit from …

Colorectal cancer (CRC) is one of the most prevalent cancer types worldwide, with a high
mortality rate due to metastasis. The tumor microenvironment (TME) contains multiple …

Purpose Immune checkpoints, as pivotal regulators of immune escape in cancer, can
motivate the emergence of immune checkpoint inhibitors (ICIs). The aim of this study is to …

Sialic acid binding Ig-like lectin 10 (Siglec10) is a member of innate immune checkpoints
that inhibits the activation of immune cells through the interaction with its ligand CD24 on …